Inquiry
Blog
Related News
In the height of summer, on Lüdao Island, guests feel right at home. On June 30, against the backdrop of deepening medical cooperation between China and Indonesia under the Belt and Road Initiative and the RCEP framework, a medical delegation from the Indonesian government visited Xiamen. As a leading enterprise deeply rooted in the fields of medical devices, medical consumables, medical equipment, diagnostic reagents, and the global healthcare supply chain, our company was invited to engage in in-depth exchanges and discussions with the delegation, jointly exploring new avenues for industry collaboration.
When the epidemic struck, government and enterprises joined forces, demonstrating their sense of responsibility through mutual support and solidarity; we delved deeply into fertile ground to usher in a new chapter. Looking back at the critical period of epidemic prevention and control, Dehua County faced an urgent shortage of防疫 supplies, leaving many medical companies unable to provide adequate support. In this moment of crisis, our company stepped forward, proactively reaching out to the Dehua County government. With a strong sense of social responsibility and highly efficient supply-chain integration capabilities, we fully committed ourselves to ensuring the supply of防疫 materials.
In 2023, many areas in Gansu Province were hit by severe flooding. The raging floods not only destroyed homes but also created hidden public health risks by spreading bacteria and viruses after the disaster. Though disasters are merciless, humanity remains compassionate. At this critical moment when epidemic prevention efforts in the affected areas are urgently needed, our company, guided by our original commitment to "medical care for the people and a sense of responsibility," proactively responded to the epidemic prevention needs of the disaster zone. We promptly allocated supplies and donated a batch of specialized protective suits to the flood-hit regions in Gansu, thereby establishing a strong safety barrier for frontline epidemic prevention workers in the aftermath of the disaster.
From June 8 to June 10, 2023, the Shenzhen International High-Performance Medical Device Exhibition was held with great success. ThinkMed Medical participated in several thematic seminars and forums at the exhibition, joining industry peers to discuss trends in the AI-driven healthcare sector and sharing its own innovative product applications as well as achievements in international expansion.
Domestic extracorporeal membrane oxygenation (ECMO) products have been approved for market launch.
Release time:
2023-01-04
In response to epidemic prevention and control requirements and to ensure the treatment needs of critically ill patients with novel coronavirus pneumonia, on January 4, 2023, the National Medical Products Administration, after review, approved the registration application for an extracorporeal cardiopulmonary support assistive device—the single-use membrane oxygenator kit—submitted by Shenzhen Hanuo Medical Technology Co., Ltd. This device is intended for adult patients with acute respiratory failure or acute cardiopulmonary failure whose conditions are difficult to manage with other treatments and who are at predictable risk of continued deterioration or death. As the first domestically developed ECMO device and consumables package, the aforementioned product possesses independent intellectual property rights and its performance indicators generally meet the level of comparable international products.
Among these, the extracorporeal cardiopulmonary support assistive device consists of a main unit, a pump drive system, an emergency pump drive system with backup batteries, a flow bubble sensor, and accompanying components as well as oxygen pipelines.
ECMO products are life-saving devices used for critically ill patients with severe novel coronavirus pneumonia who do not respond to conventional treatments. They are listed as a prescribed treatment measure in the "Guidelines for the Diagnosis and Treatment of Novel Coronavirus Pneumonia." The launch of domestically produced ECMO products will play a crucial role in meeting clinical needs, ensuring effective treatment for severe COVID-19 patients, and helping to achieve the epidemic prevention and control goals of "health protection and strict prevention."
During the registration and application process for this product, the National Medical Products Administration (NMPA) established an emergency review team in accordance with the principles of “unified command, early intervention, rapid efficiency, and scientific approval.” This team is responsible for, guides, and issues technical review guidelines, intensifies guidance on product registration and applications, accelerates the approval process, and ensures that products are swiftly brought to market while maintaining safety and efficacy, thereby promptly meeting the urgent needs of epidemic prevention and control.
The drug regulatory authority will strengthen post-market surveillance of this product to safeguard patient safety.
YESING (Xiamen) Biotechnology Co., Ltd.
Address: Unit 604, No. 11 Duiying Road, Jimei District, Xiamen City, Fujian Province
Phone:86-15160010805
Email:info@yesingglobal.com